Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase a2 activity: A randomized, controlled trial

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Johnson, Joel L ^a   Shi, Yi ^b   Snipes, Rose ^a   Janmohamed, Salim ^c   Rolfe, Timothy E ^c   Davis, Bill ^c   Postle, Anthony ^d   Macphee, Colin H ^a  

^a GLAXOSMITHKLINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CASPASE 3; DARAPLADIB; GELATINASE B; LYSOPHOSPHATIDYLCHOLINE; MESSENGER RNA; PLACEBO; BENZALDEHYDE DERIVATIVE; BIOLOGICAL MARKER; CASPASE 8; OXIME;

ADULT; ARTICLE; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; AGED; BLOOD; CAROTID STENOSIS; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; PLAQUE, ATHEROSCLEROTIC; TIME;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; BENZALDEHYDES; BIOLOGICAL MARKERS; CAROTID STENOSIS; CASPASE 3; CASPASE 8; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDARTERECTOMY, CAROTID; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LYSOPHOSPHATIDYLCHOLINES; MALE; OXIMES; PLAQUE, ATHEROSCLEROTIC; TIME FACTORS;

EID: 84895869898     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089034     Document Type: Article

References (26)

1. Dembowski E, Davidson MH (2009) A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev 29: 2-12.
2. 2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25: 923-931.
3. 2). Cardiovasc Drugs Ther 23: 73-83.
4. Wilensky RL, Macphee CH (2009) Lipoprotein-associated phospholipase A2 and atherosclerosis. Curr Opin Lipidol 20: 415-420.
5. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM (1990) Human macrophages secrete platelet activating factor acetylhydrolase. J Biol Chem 265: 9682-9687.
6. 2 in inflammation and atherosclerosis. J Am Coll Cardiol 59: 764-772.
7. Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, et al. (2011) Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways. Circ Res 108: 985-995.
8. 2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 26: 2523-2529.
9. 2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 39: 1448-1455.
10. 2 in carotid artery plaques predicts long-term cardiac outcome. Eur Heart J 30: 2930-2938.
11. 2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol 32: 1505-1512.
12. 2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375: 1536-1544.
13. Wilensky RL, Shi Y, Mohler ER III, Hamamdzic D, Burgert ME, et al. (2008) Inhibition of lipoprotein-associated phospholipase A 2 reduces complex coronary atherosclerotic plaque development. Nat Med 14: 1059-1066.
14. 2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. PLoS ONE 6(8): e23425. doi:10.1371/journal.pone.0023425.
15. Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, et al. (2008) Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118: 1172-1182.
16. White H, Held C, Stewart R, Watson D, Harrington R, et al. (2010) Study design and rationale for the clinical outcomes of the STABILITY trial (STabilization of atherosclerotic plaque by initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J 160: 655-661.
17. O'Donoghue ML, Braunwald E, White HD, Serruys P, Steg PG, et al. (2011) Study design and rationale for the stabilization of pLaques usIng darapladib-thrombolysis in myocardial infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J 162: 613-619.
18. Johnson A, Zalewski A, Janmohamed S, Sawyer J, Rolfe T, et al. (2004) Lipoprotein-associated phospholipase A2 activity, an emerging CV risk marker, can be inhibited in atherosclerotic lesions and plasma by novel pharmacologic intervention: the results of a multicenter clinical study. Circulation 110(suppl III): III-590. Abstract.
19. 2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111: 570-575.
20. 2 diminishes the death-inducing effects of oxidized LDL on human monocyte-macrophages. FEBS Lett. 505: 357-363.
21. 2 in oxidized human low density lipoprotein. J Biol Chem 283: 6428-6437.
22. 2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 51: 1632-1641.
23. Sluijter JPG, Pulskens WPC, Schoneveld AH, Velema E, Strijder CF, et al. (2006) Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 37: 235-239. (Pubitemid 43732079)
24. Fiotti N, Moretti ME, Bussani R, Altamura N, Zamolo F, et al. (2011) Features of vulnerable plaques and clinical outcome of UA/NSTEMI: relationship with matrix metalloproteinase functional polymorphisms. Atherosclerosis 215: 153-159.
25. 2 and oxidized low density lipoprotein in carotid atherosclerosis. J Lipid Res 50: 1735-1743.
26. Wang JC, Bennett M (2012) Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 111: 245-259.